AbbVie gets FDA approval for antibiotic treatment Emblaveo

AbbVie Gets FDA Approval for New Antibiotic in the Face of Rising Resistance
The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in partnership with Pfizer. AbbVie acquired its share of the asset as part of its $63 billion buyout of Allergan.
FDA approves AbbVie’s Emblaveo for intra-abdominal infections
AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in conjunction with metronidazole for people aged 18 and over with complicated intra-abdominal infections (cIAI) and limited treatment options.
AbbVie scores FDA nod for Pfizer-partnered antibiotic Emblaveo
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S.,
US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections
AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections, including those caused by drug-resistant bacteria. AbbVie and co-developer Pfizer's drug,
AbbVie’s EMBLAVEO Approved by FDA for Treatment of Complicated Intra-Abdominal Infections
Addresses the significant threat of antimicrobial resistance.
AbbVie gets FDA OK on antibiotic therapy that fights resistant bacteria
It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.
AbbVie: FDA Approves Emblaveo - Metronidazole Combination For Complicated Intra-Abdominal Infections
AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first
AbbVie gets FDA approval for antibiotic treatment Emblaveo (update)
AbbVie (NYSE:ABBV) said it has received FDA approval for the intravenous antibiotic treatment Emblaveo, which was co-developed with Pfizer (NYSE:PFE). The FDA approved Emblaveo, a combination of aztreonam and avibactam,
AbbVie Inc. stock underperforms Friday when compared to competitors
The stock's fall snapped a two-day winning streak.
The Motley Fool on MSN10d
Why AbbVie Stock Is Jumping Today
AbbVie reported its 2024 Q4 results on Friday. Investors especially liked the drugmaker's 2025 outlook. AbbVie reported ...
BioSpace10d
AbbVie Revamps Emraclidine Expectations After Mid-Stage Schizophrenia Failure
After the Phase II failure of its lead asset from Cerevel, AbbVie is resetting expectations and narrowing the clinical ...
A Glimpse Into The Expert Outlook On AbbVie Through 15 Analysts
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...
Crain's Chicago Business10d
AbbVie's new drugs help brighten 2025 earnings outlook
The North Chicago-based drugmaker is relying on newer treatments to make up for falling sales of Humira, its aging ...
STAT17h
Pharmalittle: We’re reading about Trump orders and public health, AI startups overstating their work, and more
Public health experts worry the FDA workforce will be slashed, impeding the ability of the agency to review new medicines ...
Analysts reset AbbVie stock price target after earnings
Subscribe to TheStreet's free daily newsletter 💰💵 That is why the market saw AbbVie make a number of acquisitions to expand ...
3 Dividend Stocks to Double Up on Right Now
AbbVie is a Dividend King that's quickly moving past reliance on Humira. Enbridge shouldn't be affected by potential Canadian ...